GlassScriptPhysician profile
Alexander Jon Leverett
NPI 1144900846
$6,663.48
in general payments reported to CMS, 2019-2025
63 companies · $3,048 in 2025
The $3,048 reported for 2025 was more than what 97% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $961 · 2024: $2,655 · 2025: $3,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,465 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,465.48 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $598.17 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $392.66 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $365.62 | 2023-2025 | Calquence, Enhertu, Tagrisso |
| Kite Pharma, INC. | $362.36 | 2025 | Yescarta |
| E.R. Squibb & Sons, L.L.C. | $314.71 | 2024-2025 | Opdivo, Krazati, Opdualag |
| Sobi, INC | $295.36 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $286.36 | 2023-2025 | Ninlaro, Alunbrig, Iclusig |
| Regeneron Healthcare Solutions, INC. | $255.37 | 2023-2025 | Libtayo |
| Janssen Biotech, INC. | $244.96 | 2024-2025 | Imbruvica, Darzalex, Tecvayli |
| Daiichi Sankyo INC. | $228.89 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Incyte Corporation | $228.07 | 2023-2025 | Monjuvi, Jakafi, Pemazyre |
| Lilly USA, LLC | $226.57 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Genzyme Corporation | $222.03 | 2023-2025 | |
| Pfizer INC. | $163.35 | 2023-2025 | |
| Celgene Corporation | $163.19 | 2023-2025 | Reblozyl, Pomalyst |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $157.75 | 2023-2025 | Brukinsa |
| Ipsen Biopharmaceuticals, INC | $153.29 | 2023-2025 | Onivyde, Somatuline Depot |
| Genentech USA, INC. | $123.54 | 2023-2025 | Polivy, Venclexta, Lunsumio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.85 | 2023-2025 | Gilotrif |
| Glaxosmithkline, LLC. | $110.40 | 2024-2025 | Ojjaara, Blenrep, Jemperli |
| Puma Biotechnology, INC. | $99.81 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $96.97 | 2024-2025 | |
| Acrotech Biopharma INC. | $80.82 | 2025 | Beleodaq |
| Abbvie INC. | $79.91 | 2024-2025 | |
| Astellas Pharma US INC | $63.59 | 2024-2025 | Cresemba |
| Bayer Healthcare Pharmaceuticals INC. | $63.51 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $62.97 | 2024-2025 | |
| Azurity Pharmaceuticals, INC. | $62.70 | 2025 | Danziten |
| Alexion Pharmaceuticals, INC. | $59.04 | 2023-2024 | Ultomiris |
| Kyowa Kirin, INC. | $58.98 | 2024-2025 | Poteligeo |
| Adaptive Biotechnologies Corporation | $55.92 | 2024 | Clonoseq |
| Gilead Sciences, INC. | $54.94 | 2025 | Trodelvy |
| Geron Corporation | $51.31 | 2025 | Rytelo |
| Rigel Pharmaceuticals, INC. | $48.76 | 2023-2024 | Tavalisse, Rezlidhia |
| Alnylam Pharmaceuticals INC. | $47.91 | 2023-2024 | Givlaari |
| Pharmaessentia USA Corporation | $39.46 | 2024 | Besremi |
| Shield Therapeutics INC | $37.03 | 2025 | |
| Exelixis INC. | $35.38 | 2023-2025 | Cabometyx |
| Seagen INC. | $35.33 | 2023 | Adcetris, Tukysa |
| Stemline Therapeutics INC. | $34.89 | 2024 | Orserdu |
| Pharmacosmos Therapeutics INC. | $34.85 | 2024 | Cosela |
| Karyopharm Therapeutics INC. | $28.11 | 2024-2025 | Xpovio |
| Eisai INC. | $26.43 | 2025 | |
| Blueprint Medicines Corporation | $26.24 | 2024 | Ayvakit |
| Taiho Oncology, INC. | $25.29 | 2025 | |
| Recordati_rare_diseases_inc. | $23.83 | 2023 | Sylvant |
| Genmab U.S., INC. | $23.58 | 2024 | Epkinly |
| Pharmaand Gmbh | $23.37 | 2025 | Rubraca |
| Tolmar, INC. | $23.37 | 2025 | Eligard, Rubraca |
| Forte Bio-Pharma LLC | $23.20 | 2023 | Prolate, Nalocet |
| Mirati Therapeutics, INC. | $22.95 | 2023 | Krazati |
| Novocure INC. | $21.65 | 2024 | Optune |
| Adc Therapeutics America, INC. | $18.83 | 2025 | |
| Emd Serono, INC. | $18.60 | 2024 | |
| Servier Pharmaceuticals LLC | $18.60 | 2024 | |
| Spectrum Pharmaceuticals INC. | $18.02 | 2025 | Rolvedon |
| Deciphera Pharmaceuticals INC. | $17.89 | 2024 | Qinlock |
| Caris Mpi, INC. | $17.78 | 2025 | Mi Cancer Seek |
| Beone Medicines USA, INC. | $17.04 | 2025 | Brukinsa |
| Tersera Therapeutics LLC | $15.45 | 2025 | Xermelo |
| Amgen INC. | $15.08 | 2023 | Lumakras |
| Myriad Genetic Laboratories, INC. | $14.68 | 2024 | Myrisk |
| Cti Biopharma Corp. | $13.91 | 2023 | Vonjo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Leverett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.